<VariationArchive VariationID="18455" VariationName="NC_000001.10:g.17375249_17390927del15679" VariationType="Deletion" Accession="VCV000018455" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-05-01" DateCreated="2016-01-09" MostRecentSubmission="2023-10-21">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="33494" VariationID="18455">
      <GeneList>
        <Gene Symbol="LOC129929542" FullName="ATAC-STARR-seq lymphoblastoid active region 277" GeneID="129929542" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>1p36.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17053912" stop="17053971" display_start="17053912" display_stop="17053971" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_025791756.1" start="1469107" stop="1469166" display_start="1469107" display_stop="1469166" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC129929543" FullName="ATAC-STARR-seq lymphoblastoid active region 278" GeneID="129929543" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>1p36.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17054522" stop="17054571" display_start="17054522" display_stop="17054571" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_025791756.1" start="1469717" stop="1469766" display_start="1469717" display_stop="1469766" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="SDHB" FullName="succinate dehydrogenase complex iron sulfur subunit B" GeneID="6390" HGNC_ID="HGNC:10681" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>1p36.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17018722" stop="17054032" display_start="17018722" display_stop="17054032" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_025791756.1" start="1433916" stop="1469227" display_start="1433916" display_stop="1469227" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="17345216" stop="17380664" display_start="17345216" display_stop="17380664" Strand="-" />
          </Location>
          <OMIM>185470</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000001.10:g.17375249_17390927del15679</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p36.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="17375249" stop="17390927" display_start="17375249" display_stop="17390927" variantLength="15679" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17048754" stop="17064432" display_start="17048754" display_stop="17064432" variantLength="15679" />
      </Location>
      <OtherNameList>
        <Name>15.69-KB DEL, EX1</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.17375249_17390927del15679" Assembly="GRCh37">
            <Expression>NC_000001.10:g.17375249_17390927del15679</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.17048754_17064432del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.17048754_17064432del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="185470.0017" DB="OMIM" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000001.10:g.17375249_17390927del15679 AND Paragangliomas 4" Accession="RCV000013635" Version="27">
        <ClassifiedConditionList TraitSetID="3475">
          <ClassifiedCondition DB="MedGen" ID="C1861848">Paragangliomas 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2009-04-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2009-04-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-01-09" MostRecentSubmission="2023-10-21">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16258955</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18057081</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19389109</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3475" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3267" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 4</ElementValue>
                <XRef ID="Paragangliomas+4/5581" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007273" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CAROTID BODY TUMORS AND MULTIPLE EXTRAADRENAL PHEOCHROMOCYTOMAS</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0017" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0010" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0023" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0019" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0009" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, extraadrenal and cervical paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomas, hereditary extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, familial extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma, familial malignant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome (Paragangliomas 4)</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10546" />
                <XRef ID="10546" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="review">
                <ID Source="PubMed">20816580</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C1861848" DB="MedGen" />
              <XRef ID="MONDO:0007273" DB="MONDO" />
              <XRef Type="MIM" ID="115310" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33882" SubmissionDate="2016-01-07" DateLastUpdated="2023-10-21" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="185470.0017_PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4" title="SDHB, 15.69-KB DEL, EX1_PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4" />
        <ClinVarAccession Accession="SCV000033882" DateUpdated="2023-10-21" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2009-04-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Cascon et al. (2006) detected a germline deletion affecting SDHB exon 1 in a 30-year-old Portuguese male with a secreting retroperitoneal paraganglioma (PPGL4; 115310) and an uncertain family history. The authors found the same loss of SDHB exon 1 in a 14-year-old female proband from a Spanish family with a history of PGL. The proband was admitted to hospital with hypertension and later diagnosed with catecholamine-secreting PGL of the retroperitoneum. The proband's father was diagnosed at age 48 with PGL of the Zuckerkandl organ, which metastasized to the liver at age 53. Bone metastases were found 4 years later. The brothers of the proband also had high levels of dopamine in their urine. Cascon et al. (2006) detected the germline deletion in all 3 of these relatives of the proband. No deletions affecting the SDHC or SDHD genes were found in any patients. Analysis of the genomic structure of the SDHB gene revealed a high density of Alu repeats within the first intron. The authors suggested that Alu-mediated recombination may account for the observed clustering of a gross deletion hotspot.</Attribute>
              <Citation>
                <ID Source="PubMed">16258955</ID>
              </Citation>
              <XRef DB="OMIM" ID="115310" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Cascon et al. (2008) reported 3 additional families, 2 of Spanish and 1 of French origin, with the SDHB exon 1 deletion. In the first Spanish family, the proband was diagnosed at age 19 with retroperitoneal PGL, and multiple metastases in bone, hypophysis, retroperitoneum, and liver. Her sister was diagnosed with an adrenal neuroblastoma with metastasis at age 5 years of age. The proband in the second Spanish family was diagnosed with abdominal PGL and renal oncocytoma at age 17; both were surgically resected. Ten years later she showed bone metastasis. In the French family, the proband had malignant pheochromocytoma (PCC) at age 27 years and died as a result of the disease. He had a relative with benign PCC, diagnosed at age 30 years. Molecular analysis revealed that same deletion breakpoints in all Spanish families resulting in a 15.69-kb deletion, including the 2 families previously reported by Cascon et al. (2006), and a different breakpoint junction in the French family, resulting in a 20.3-kb deletion (185470.0018). Haplotype analysis indicated a founder effect in the Spanish families for the 15.69-kb deletion. All Spanish patients originally came from a small area in the northwest region of the Iberian peninsula.</Attribute>
              <Citation>
                <ID Source="PubMed">18057081</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">16258955</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Solis et al. (2009) reported a large 5-generation family of Spanish Mexican descent with the same 15.69-kb SDHB founder deletion previously described by Cascon et al. (2006, 2008). Eleven of 41 mutation carriers developed PGL in various locations, including the carotid body, adrenal gland, pelvis, and thorax. Penetrance of the founder deletion was estimated to be 35% by age 40 years.</Attribute>
              <Citation>
                <ID Source="PubMed">19389109</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">16258955</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">18057081</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHB" />
          </GeneList>
          <Name>SDHB, 15.69-KB DEL, EX1</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">15.69-KB DEL, EX1</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="185470.0017" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="33882" TraitType="Disease" MappingType="Name" MappingValue="PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4" MappingRef="Preferred">
        <MedGen CUI="C1861848" Name="Paragangliomas 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

